| アブストラクト | STUDY OBJECTIVES: Mogamulizumab is an important treatment for T-cell leukemia and lymphoma. Adverse cardiovascular events (ACE) after mogamulizumab therapy have not been investigated. The aim of the study is to investigate ACE occurrence after mogamulizumab therapy. METHODS: The International World Health Organization database, VigiBase, was analyzed from January 2013 to August 2019 for all adverse events, including ACE, that occurred after mogamulizumab treatment. ACE was defined as: cardiac death, myocardial infarction, heart failure, myocarditis, arrhythmia, vasculitis, thrombosis, palpitations and new hypertension. RESULTS: ACE after mogamulizumab therapy affected 28 out of 650 unique patients (4.3%). Heart failure (42.8%) and ventricular arrhythmias (17.85%) were most common. ACE accounted for 10% of all fatal adverse outcomes, and 25% of all ACE were fatal. Time to fatal outcome was significantly shorter for patients with ACE compared to non-cardiovascular events, with a mean of 7.7 days (SD 6.91) vs 73 days (SD 90.7), p = 0.017, respectively. There was an increased total number of adverse cardiovascular events in patients greater than 65 and in Asian countries. CONCLUSIONS: Cardiovascular toxicity with mogamulizumab is a possible early occurring adverse outcome associated with high mortality. |
|---|
| ジャーナル名 | American heart journal plus : cardiology research and practice |
|---|
| Pubmed追加日 | 2021/10/6 |
|---|
| 投稿者 | Kwan, Jennifer M; Henry, Mariana L; Cook, Kirstin; Higgins, Angela; Cuomo, Jason; Foss, Francine; Baldassarre, Lauren A |
|---|
| 組織名 | Section of Cardiovascular Medicine, Yale University School of Medicine, New;Haven, CT, United States of America.;Department of Neurosurgery, University of California, Los Angeles School of;Medicine, Los Angeles, CA, United States of America.;Section of Hematology, Yale University School of Medicine, New Haven, CT, United;States of America. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/38559371/ |
|---|
